Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probiotics and Crohn's disease.

C Prantera1, M L Scribano

  • 1Division of Gastroenterology, S. Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|November 1, 2002
PubMed
Summary

Lactobacillus rhamnosus GG did not reduce endoscopic or clinical recurrence in Crohn's disease patients one year post-surgery. This probiotic showed no significant benefit over placebo for managing Crohn's disease activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial.

European review for medical and pharmacological sciences·2020
Same author

Letter: budesonide MMX for ulcerative colitis?

Alimentary pharmacology & therapeutics·2014
Same author

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.

Alimentary pharmacology & therapeutics·2009
Same author

Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease.

Journal of neurology·2008
Same author

Antibiotic use in Crohn's disease: why and how?

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.

Alimentary pharmacology & therapeutics·2007

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Crohn's disease management often involves antibiotics, but concerns exist regarding side effects, bacterial resistance, and disruption of gut microbiota.
  • Probiotic interventions, specifically manipulating enteric flora, present a potential alternative for managing inflammatory bowel diseases like Crohn's disease.
  • Investigating novel therapeutic strategies is crucial for improving patient outcomes and reducing disease recurrence after surgery.

Purpose of the Study:

  • To evaluate the efficacy of Lactobacillus rhamnosus strain GG in reducing endoscopic recurrence and lesion severity one year post-surgery for Crohn's disease.
  • To assess the impact of this probiotic on the clinical recurrence rate of Crohn's disease.
  • To compare the outcomes of probiotic supplementation versus placebo in patients undergoing surgery for Crohn's disease.

Related Experiment Videos

Main Methods:

  • A randomized controlled trial involving 45 patients with Crohn's disease.
  • Participants were assigned to receive either Lactobacillus rhamnosus strain GG or a placebo.
  • Treatment duration was 12 months, with assessments at one year to evaluate endoscopic and clinical recurrence.

Main Results:

  • No statistically significant difference was observed in endoscopic remission rates between the probiotic and placebo groups.
  • Clinical remission rates also showed no significant improvement in the group receiving Lactobacillus rhamnosus GG compared to placebo.
  • The study found no discernible benefit of this probiotic in preventing or reducing recurrence of Crohn's disease lesions post-surgery.

Conclusions:

  • Lactobacillus rhamnosus strain GG did not demonstrate efficacy in reducing endoscopic or clinical recurrence of Crohn's disease within one year of surgical intervention.
  • The findings suggest that this specific probiotic strain is not a beneficial adjunct therapy for preventing post-operative recurrence in Crohn's disease patients.
  • Further research may be needed to explore other probiotic strains or therapeutic approaches for managing Crohn's disease recurrence.